Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Renal Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Renal Cancer
    New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
    Vitespen Shows No Increased Survival in Postoperative Renal Cell Carcinoma Patients - (DGNews)
    TopAbstracts in Renal Cancer 06/25/2008 - (DGNews)
    Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
    TopAbstracts in Renal Cancer 06/11/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Renal Cancer
    • Targeted Therapies Show Activity as First-Line Treatment of Renal Cell Carcinoma
    • Emerging Therapies and Combination Therapy as the Future of Renal Cell Carcinoma Treatment
    • Utilizing and Improving Prognostic Markers in Determining Best Treatment of Renal Cell Carcinoma
    • New Science and Therapeutic Advances in the Treatment of Renal Cell Carcinoma: A Case Study Review
      Monographs in Renal Cell Carcinoma

      Webcasts/CME archive

       Recent cases - Renal Cancer
        Perirenal Schwannoma: A Case Report
        Surgical Treatment of a Rare Primary Renal Carcinoid Tumor with Liver Metastasis
        Late Pulmonary Metastases of Renal Cell Carcinoma Immediately after Post-Transplantation Immunosuppressive Treatment: A Case Report
        Cold Saline Irrigation of the Renal Pelvis During Radiofrequency Ablation of a Central Renal Neoplasm: A Case Report
        Acute Airway Failure Secondary to Thyroid Metastasis from Renal Carcinoma

        Cases archive
          




        my personal edition > renal cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Survival Advantage Seen With Temsirolimus for Renal Cell Cancer: Presented at ASCO

        By Ed Susman

        ATLANTA, G.A. -- June 4, 2006 -- Patients with renal cell carcinoma with poor prognosis live longer if they receive the investigative drug temsirolimus rather than standard interferon treatment, according to interim results presented here at the American Society of Clinical Oncology 2006 Annual Meeting (ASCO).

        This is the first trial to validate the theory that the mammalian target of papamycin (mTOR) is a target for the treatment of cancer, said Gary Hudes, MD, director of genitourinary oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

        Dr. Hudes explained that the mammalian target of rapamycin (mTOR) controls the molecular cascade of events that leads to cell proliferation and angiogenesis. Although mTOR exists in all cells, it is overexpressed in cancer cells. The researchers theorized that by attacking this target in cancer cells the damage will be limited to the malignancy rather than to healthy cells.

        The phase 3 trial, presented during a press briefing on June 4th, randomized patients to treatment with subcutaneous interferon alone, intravenous temsirolimus, or a combination of temsirolimus and interferon.

        Interferon was administered at a dose escalated from 3 million units to 18 million units 3 times a week, temsirolimus was dosed at 25 mg once a week, and the combination regimen consisted of temsirolimus 15 mg plus 6 million units of interferon 3 times weekly.

        Among 626 patients enrolled at 209 sites in 26 countries, median survival was 7.3 months in the interferon patients, 10.9 months in the temsirolimus arm, and 8.4 months in the combination arm.

        The difference between temsirolimus and interferon monotherapy reached statistical significance at the P =.0069 level. The 2.6-month survival gain represents a 49% increase.

        "Temsirolimus 25 mg intravenously administered weekly can be considered standard therapy for patients with metastatic renal cell cancer and poor-risk factors," Dr. Hudes said.

        The trial was sponsored by Wyeth Research.


        [Presentation title: A Phase 3, Randomized, 3-Arm Study of Temsirolimus (TEMSR) or Interferon-Alpha (IFN) or the Combination of TEMSR + IFN in the Treatment of First-Line, Poor-Risk Patients With Advanced Renal Cell. Abstract LBA4]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send